Medicure Inc. (CVE:MPH – Get Free Report)’s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$1.22 and traded as low as C$1.14. Medicure shares last traded at C$1.14, with a volume of 100 shares.
Medicure Stock Performance
The company has a market cap of C$11.90 million, a PE ratio of -3.45 and a beta of 0.91. The company has a current ratio of 2.03, a quick ratio of 1.29 and a debt-to-equity ratio of 4.65. The business has a fifty day moving average of C$1.22 and a 200-day moving average of C$1.17.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Articles
- Five stocks we like better than Medicure
- You Still Think Silver’s a Joke? Watch What Happens Next.
- A U.S. “birthright” claim worth trillions – activated quietly
- A month before the crash
- Wall Street ‘Sleeper Stock’ Could Become #1 Stock of 2026
- YDES Could Be 2026’s Biotech Breakthrough
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
